Claim: reduced eGFR lowers remission odds, but biologic/tsDMARD therapy remains usable in RA

Grounding: In a multicentre prospective CorEvitas registry cohort of 12,123 biologic or targeted synthetic DMARD initiations in rheumatoid arthritis, reduced eGFR (<60 mL/min per 1.73 m2) was associated with a lower chance of CDAI remission (adjusted HR 0.76, 95% CI 0.66-0.88), yet the authors still concluded these therapies are generally well tolerated and effective options.
Claim: For RheumaAI, chronic kidney disease should be treated as a risk-stratifier for expected remission and follow-up intensity, not as an automatic reason to exclude biologic or targeted synthetic DMARD treatment.
Limitation: This is observational registry evidence from a mostly non-Hispanic White US cohort, so it cannot prove causality or define a universal CKD-specific sequencing rule, and it does not replace individualized renal dosing or nephrology input.
Reference: Fukui S, Orbo HS, Tedeschi SK, et al. Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study. Lancet Rheumatol. 2026. DOI: 10.1016/S2665-9913(26)00046-9. PMID: 42034110.